期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

高敏C-反应蛋白对房颤药物复律后复发的远期预测价值 被引量：1

暂未订购
导出
摘要 目的研究基线CRP水平与心房颤动(房颤)药物复律后远期复发间的关系。方法入选43例持续性房颤患者,根据基线CRP水平把患者分为2组(0～4mg/L和≥4mg/L)。所有患者通过药物复律,并且接受胺碘酮维持窦性节律的治疗。随访观察3年后,了解基线CRP水平与房颤复发间的关系。结果在3年的随访期内,有74.7%的患者复发房颤。在CRP0～4mg/L组,房颤复发率明显降低,其差异有显著性。结论在预测房颤复发上,基线CRP水平有独立的预测价值。
作者 章宏祥 毛建华 钱钧 刘永宁 侯发琴
机构地区 皖南医学院附属马鞍山市中心医院心内科
出处 《中国医刊》 CAS 2010年第2期45-46,共2页 Chinese Journal of Medicine
关键词 高敏C-反应蛋白 心房颤动 药物复律
分类号 R541 [医药卫生—心血管疾病]
  • 相关文献

参考文献9

  • 1Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-anatysis [ J ]. J Am Coll Cardiol, 2007,49 : 1642 - 1648.
  • 2Loricchio ML, Cianfrocca C, Pasceri V, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion[ J]. Am J Cardiol,2007, 99:1421 -1424.
  • 3Fujiki A, Sakamoto T, Nishida K, et al. Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation [ J ]. J Cardiovasc Phannacol,2007,50: 264 - 266.
  • 4Demellis? J; Panaretou? M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation [ J]. Acta cardiol,2001,56 (6) : 375 - 380.
  • 5朱平辉,何华,刘晓惠,康俊萍,马长生.非瓣膜病房颤用华法林抗凝治疗的最佳初始剂量研究[J].中国医刊,2008,43(1):36-37. 被引量：9
  • 6Lally JA, Gnall EM, Seltzer J, et al. Non-antiarrhythmie drugs in atrial fibrillation: A review of non-antiarrhythmic agents in prevention of atrial fibrillation [ J ]. J Cardiovasc Electrophysiol, 2007,18: 1222 - 1228.
  • 7Iu T, Li L, Korantzopoulos P, Liu E, et al.Statin use and development of atrial fibrillation : A systematic review and meta-analysis of randomized clinical trials and observational studies[J]. Int J Cardiol,2008,126: 160 - 170.
  • 8刘小慧,罗太阳,杜昕.醛固酮与心房间质重构和心房颤动[J].中国医刊,2008,43(3):31-34. 被引量：13
  • 9Korantzopoulos P, Kolettis TM, Kountouris E, et at. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation[ J]. Int J Cardiol,2005 ,102: 321 - 326.

二级参考文献20

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量：1408
  • 2黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动：目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量：270
  • 3裴德安,李莉,徐志云,邹良建,张宝仁,黄盛东,郝家骅,王志农.心房颤动患者心房组织醛固酮水平与心房结构重构的相关性研究[J].第二军医大学学报,2007,28(2):170-174. 被引量：9
  • 4Petersen P. Thmmoembolic complications in atrial fibrillation [ J ]. Stroke,1990,21 : 4 - 13.
  • 5SPORTIF Ⅲ Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation ( SPORTIF Ⅲ ) : randomized controlled trial[ J]. Lancet,2003,362: 1691 - 1698.
  • 6Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial [ J ]. JAMA, 2005,293: 690 - 698.
  • 7Wallentin L, Ezekowitz M, Simmers TA, et al. PETRO-investigators. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin[ J]. Eur Heart J. 2005,26( suppl):482.
  • 8Stroke Prevention in Atrial Fibrillation Investigators. Stroke Preventionin Atrial Fibrillation Study. Final results[J]. Circulation,1991, 84:527 -539.
  • 9Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis [J]. Ann Intern Med,1999,131:492 -501.
  • 10Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation : a report of the American College of Cardiology/American Heart Association Task Forge on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines ( Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Circulation, 2006,114(7) : e257-e354.

共引文献20

同被引文献26

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量：1408
  • 2黄健,汪晓云,王惟,廖贵红,鲁玉明.vWF、P-选择素、SOD、MDA与心功能不全关系的研究[J].中国民康医学,2005,17(5):219-220. 被引量：5
  • 3来晏,金炜,温沁竹,张建军,孙宝贵.急性冠脉综合征P选择素表达的意义[J].中国医刊,2007,42(8):45-46. 被引量：4
  • 4Pongratz G, Brandt-Pohlmann M, Henneke KH, et al. Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation [ J]. Chest, 1997,111 (4) : 929- 933.
  • 5Feng D, D'Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation ( the Framingham Offspring Study) [ J]. Am J Cardiol, 2001,87(2) :168-171.
  • 6McEver RP, Martin MN. A monoclonal antibody to a membrane glyeoprotein binds only to activated platelets [ J ]. J Biol Chem, 1984,259( 15 ) :9799-9804.
  • 7Qi C, Wei B, Zhou W, et al. P-selectin-mediated platelet adhe- sion promotes tumor growth [ J ]. Oncotarget, 2015,6 ( 9 ) : 6584- 6596.
  • 8Merten M, Thiagarajan P. P-selectin expression on platelets deter- mines size and stability of platelet aggregates [ J ]. Circulation, 2000,102(16):1931-1936.
  • 9Kamath S, Blann AD, Caine GJ, et al. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation[ J~. Stroke, 2002,33 (5) : 1237-1242.
  • 10Otterstad JE, Kirwan BA, Lubsen J, et al. Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease [ J ]. Scand Cardiovasc J, 2006, 40 (3) : 152-159.

引证文献1

二级引证文献1

中国医刊
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部